Top 5 Takeaways Full FDA Approval: On January 31, 2022, the FDA granted full approval to the Moderna COVID-19 vaccine for individuals aged ≥18 years. ACIP Recommendation: On February 4,

Top 5 Takeaways High Adverse Event Rate: 91.4% of patients reported experiencing at least one adverse event during treatment with nifurtimox. Demographic Concentration: Most patients were adults aged ≥18 years

Top 5 Takeaways High Specificity: The study found that the specificity of DENV and SARS-CoV-2 enzyme-linked immunosorbent assays (ELISAs) was ≥98%, indicating minimal cross-reactivity. Minimal Cross-Reactivity: Results showed minimal levels

Top 5 Takeaways Increased Hospitalization Rates: During the Omicron variant predominance, infants and children aged 0–4 years were hospitalized at approximately five times the rate compared to the Delta variant

Top 5 Takeaways Vaccine Effectiveness: Two doses of the Pfizer-BioNTech COVID-19 vaccine reduced the risk of Omicron infection by 31% among children aged 5–11 years and by 59% among adolescents